ArticleJournal for immunotherapy of cancer2023

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Andrew L Coveler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.